Intercept Pharmaceuticals Inc (ICPT) Position Increased by SG Americas Securities LLC

SG Americas Securities LLC increased its holdings in shares of Intercept Pharmaceuticals Inc (NASDAQ:ICPT) by 126.0% in the 4th quarter, Holdings Channel reports. The institutional investor owned 28,531 shares of the biopharmaceutical company’s stock after purchasing an additional 15,904 shares during the period. SG Americas Securities LLC’s holdings in Intercept Pharmaceuticals were worth $1,667,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the stock. Fisher Asset Management LLC lifted its position in shares of Intercept Pharmaceuticals by 196.6% during the 4th quarter. Fisher Asset Management LLC now owns 39,852 shares of the biopharmaceutical company’s stock worth $2,328,000 after buying an additional 26,416 shares during the last quarter. Fox Run Management L.L.C. lifted its position in shares of Intercept Pharmaceuticals by 122.3% during the 4th quarter. Fox Run Management L.L.C. now owns 19,786 shares of the biopharmaceutical company’s stock worth $1,156,000 after buying an additional 10,886 shares during the last quarter. Bank of Montreal Can raised its position in Intercept Pharmaceuticals by 15.8% in the fourth quarter. Bank of Montreal Can now owns 19,073 shares of the biopharmaceutical company’s stock valued at $1,115,000 after purchasing an additional 2,603 shares during the last quarter. GSA Capital Partners LLP bought a new position in Intercept Pharmaceuticals in the third quarter valued at about $731,000. Finally, Ladenburg Thalmann Financial Services Inc. raised its position in Intercept Pharmaceuticals by 292.0% in the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 7,582 shares of the biopharmaceutical company’s stock valued at $440,000 after purchasing an additional 5,648 shares during the last quarter. Institutional investors and hedge funds own 74.37% of the company’s stock.

Intercept Pharmaceuticals Inc (ICPT) opened at $53.29 on Friday. Intercept Pharmaceuticals Inc has a 1 year low of $51.53 and a 1 year high of $135.59. The company has a debt-to-equity ratio of 3.15, a quick ratio of 5.95 and a current ratio of 5.95. The stock has a market capitalization of $1,457.93, a PE ratio of -3.60 and a beta of -2.13.

Several equities analysts have commented on ICPT shares. Bank of America dropped their target price on Intercept Pharmaceuticals from $102.00 to $73.00 and set an “underperform” rating for the company in a research report on Friday, October 13th. Oppenheimer reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a research report on Tuesday, October 24th. Laidlaw upgraded Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $90.00 target price for the company in a research report on Wednesday, November 1st. Cantor Fitzgerald upgraded Intercept Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $69.00 target price for the company in a research report on Wednesday, November 1st. Finally, Cowen reiterated a “buy” rating and issued a $112.00 target price on shares of Intercept Pharmaceuticals in a research report on Wednesday, November 1st. Five equities research analysts have rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $134.86.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://sportsperspectives.com/2018/02/09/intercept-pharmaceuticals-inc-icpt-position-increased-by-sg-americas-securities-llc.html.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Want to see what other hedge funds are holding ICPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intercept Pharmaceuticals Inc (NASDAQ:ICPT).

Institutional Ownership by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply